Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

861 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase II study of trastuzumab and cisplatin as first-line therapy in patients with HER2-positive advanced gastric or gastroesophageal junction cancer.
Grávalos C, Gómez-Martín C, Rivera F, Alés I, Queralt B, Márquez A, Jiménez U, Alonso V, García-Carbonero R, Sastre J, Colomer R, Cortés-Funes H, Jimeno A. Grávalos C, et al. Among authors: rivera f. Clin Transl Oncol. 2011 Mar;13(3):179-84. doi: 10.1007/s12094-011-0637-6. Clin Transl Oncol. 2011. PMID: 21421462 Clinical Trial.
Recommendations on current approach to gastric cancer.
Rivera F, Carrato A, Grávalos C, Pericay C, Sastre J, Aranda E. Rivera F, et al. Clin Transl Oncol. 2009 Aug;11(8):518-25. doi: 10.1007/s12094-009-0396-9. Clin Transl Oncol. 2009. PMID: 19661026
Current controversies in the management of metastatic colorectal cancer.
Vera R, Alonso V, Gállego J, González E, Guillén-Ponce C, Pericay C, Rivera F, Safont MJ, Valladares-Ayerbes M. Vera R, et al. Among authors: rivera f. Cancer Chemother Pharmacol. 2015 Oct;76(4):659-77. doi: 10.1007/s00280-015-2808-6. Epub 2015 Jun 26. Cancer Chemother Pharmacol. 2015. PMID: 26113053 Review.
Lauren subtypes of advanced gastric cancer influence survival and response to chemotherapy: real-world data from the AGAMENON National Cancer Registry.
Jiménez Fonseca P, Carmona-Bayonas A, Hernández R, Custodio A, Cano JM, Lacalle A, Echavarria I, Macias I, Mangas M, Visa L, Buxo E, Álvarez Manceñido F, Viudez A, Pericay C, Azkarate A, Ramchandani A, López C, Martinez de Castro E, Fernández Montes A, Longo F, Sánchez Bayona R, Limón ML, Diaz-Serrano A, Martin Carnicero A, Arias D, Cerdà P, Rivera F, Vieitez JM, Sánchez Cánovas M, Garrido M, Gallego J. Jiménez Fonseca P, et al. Among authors: rivera f. Br J Cancer. 2017 Sep 5;117(6):775-782. doi: 10.1038/bjc.2017.245. Epub 2017 Aug 1. Br J Cancer. 2017. PMID: 28765618 Free PMC article.
First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD).
Carrato A, Abad A, Massuti B, Grávalos C, Escudero P, Longo-Muñoz F, Manzano JL, Gómez A, Safont MJ, Gallego J, García-Paredes B, Pericay C, Dueñas R, Rivera F, Losa F, Valladares-Ayerbes M, González E, Aranda E; Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD). Carrato A, et al. Among authors: rivera f. Eur J Cancer. 2017 Aug;81:191-202. doi: 10.1016/j.ejca.2017.04.024. Epub 2017 Jun 19. Eur J Cancer. 2017. PMID: 28633089 Free article. Clinical Trial.
Genomic Profiling of HER2-Positive Gastric Cancer: PI3K/Akt/mTOR Pathway as Predictor of Outcomes in HER2-Positive Advanced Gastric Cancer Treated with Trastuzumab.
Díaz-Serrano A, Angulo B, Dominguez C, Pazo-Cid R, Salud A, Jiménez-Fonseca P, Leon A, Galan MC, Alsina M, Rivera F, Plaza JC, Paz-Ares L, Lopez-Rios F, Gómez-Martín C. Díaz-Serrano A, et al. Among authors: rivera f. Oncologist. 2018 Sep;23(9):1092-1102. doi: 10.1634/theoncologist.2017-0379. Epub 2018 Apr 26. Oncologist. 2018. PMID: 29700210 Free PMC article.
SEOM-GEMCAD-TTD Clinical Guideline for the diagnosis and treatment of esophageal cancer (2021).
Fernández-Montes A, Alcaide J, Alsina M, Custodio AB, Franco LF, Gallego Plazas J, Gómez-Martín C, Richart P, Rivera F, Martin-Richard M. Fernández-Montes A, et al. Among authors: rivera f. Clin Transl Oncol. 2022 Apr;24(4):658-669. doi: 10.1007/s12094-022-02801-2. Epub 2022 Mar 26. Clin Transl Oncol. 2022. PMID: 35347573 Free PMC article. Review.
Is aflibercept an optimal treatment for wt RAS mCRC patients after progression to first line containing anti-EGFR?
Vera R, Mata E, González E, Juez I, Alonso V, Iranzo P, Martínez NP, López C, Cabrera JM, Safont MJ, Ruiz-Casado A, Salgado M, González B, Escudero P, Rivera F, Pericay C. Vera R, et al. Among authors: rivera f. Int J Colorectal Dis. 2020 Apr;35(4):739-746. doi: 10.1007/s00384-020-03509-x. Epub 2020 Feb 15. Int J Colorectal Dis. 2020. PMID: 32062727
861 results